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Abstract Silencing of fibronectin (FN) expression seems to be
one of the key mechanisms underlying metastatic behaviour. An
inverse correlation exists between FN expression levels and the
metastatic potential of two related murine mammary adenocar-
cinomas, M3 and MM3. Primary cultures of M3 tumour, which
is moderately metastatic to lung (40% incidence), show a
conspicuous FN extracellular matrix (ECM) and high levels of
FN mRNA, while primary cultures of the highly metastatic
MM3 tumour (95% lung incidence) are negative for FN in
immunofluorescence and show at least 40-fold lower levels of FN
mRNA, only detectable by RT-PCR, with a different pattern of
alternatively spliced EDI isoforms compared to M3 cells. We
show that the FN promoter sequence is not altered in MM3 cells.
Transfection experiments with CAT constructs indicate that
silencing occurs at the transcriptional level, involving the 220-bp
proximal promoter region.
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1. Introduction
Integrins and their ligands are involved in the malignant
behaviour of tumour cells. Overexpression of K5L1 or K2L1
integrins suppresses tumorigenesis [1,2], while blocking of in-
tegrin function with either RGD-peptides or speci¢c antibod-
ies [3,4] reduces both tumorigenicity and metastasis. Fibronec-
tin (FN) is the best characterised extracellular matrix (ECM)
protein among integrin ligands. Loss of cell surface FN ac-
companies oncogenic transformation and it has been corre-
lated with the acquisition of tumorigenic and metastatic po-
tentials [5]. Conversely, reappearance of FN expression
elicited by either FN cDNA transfection [6,7] or signalling
activation [8,9] have been shown to revert tumorigenic and/
or metastatic phenotypes. These ¢ndings con¢rm early obser-
vations that the addition of puri¢ed FN to transformed cells
in culture restores normal morphology [10] and support the
potential therapeutic use of FN, as recently shown by Pasqua-
lini et al. [11], who found that a polymeric form of FN (super-
¢bronectin) is able to act as a powerful antimetastatic agent
against multiple tumour types.
We have previously described an inverse correlation be-
tween FN expression levels and the metastatic potential of
two related murine mammary adenocarcinomas. Primary cul-
tures of M3 tumours, moderately metastatic to lung, have a
conspicuous FN ECM and high levels of FN mRNA, while
primary cultures of the highly metastatic MM3 tumours, de-
rived from M3 tumour by in vivo passage, show no FN ECM
and undetectable FN mRNA levels by RNase mapping [12].
An established cell line derived from MM3 primary cultures
(termed LMM3) [13], permanently transfected with constructs
expressing full length FN cDNA under the control of a viral
promoter exhibits reduced metastatic capacity compared to
untransfected cells [6]. Though loss of FN in transformed cells
was the original observation that led to the discovery and
characterisation of FN [14,15] and remains the most remark-
able regulatory event of this protein, little is known about the
precise mechanism involved. This report explores the molec-
ular bases of FN expression downregulation in the highly
metastatic MM3 cells. We show that though the proximal
FN promoter region has no sequence alterations, FN
mRNA levels are at least 40-fold lower in MM3 cells than
in M3 cells, revealing an inversion in the relative abundance
of two alternatively spliced FN isoforms. By transient expres-
sion of FN promoter-CAT constructs we demonstrate that
low FN mRNA levels are due to reduced transcription, in-
volving the 220-bp proximal promoter region.
2. Materials and methods
2.1. Tumours
For all the experiments we used primary cultures of two BALB/c
mammary adenocarcinomas with di¡erent lung metastatic potential.
Brie£y, M3 tumour presents a latency of 6^8 days and has a 40%
incidence of lung metastases. The MM3 variant was obtained by
Colombo et al. [16], following successive s.c. trocar implants of M3
lung metastases into the £ank of syngenic mice. Once MM3 achieved
a stable growth and metastatic behaviour, it was further maintained
by grafts of s.c. tumour fragments. This variant presents a longer
latency (12^14 days) and a 95% incidence of lung metastases [17].
Both tumours were maintained by subcutaneous trocar implants
into female BALB/c mice.
2.2. Cell cultures
Primary cell suspensions of M3 or MM3 tumours were prepared by
enzymatic digestion of tumour fragments with 0.01% pronase (Sigma)
and 0.0035% DNase (Sigma) in MEM (41500, Gibco-BRL) medium.
Cells were cultured in MEM supplemented with 10% heat inactivated
foetal calf serum, 2 mM L-glutamine and 80 mg/ml gentamycin at
37‡C. M3 and MM3 cell monolayers were mostly composed of epi-
thelioid polyhedral cells with less than 2% contaminating macro-
phages and ¢broblast-like cells. For some experiments we also used
LM3 and LMM3 cell lines derived from M3 and MM3 tumours,
respectively [13]. Both cell lines were maintained in MEM supple-
mented with 5% FCS plus L-glutamine and gentamycin as mentioned
above.
2.3. Cell treatments
Cells were treated for 24 h in 1% (v/v) foetal calf serum with one of
the following reagents: 10 nM okadaic acid (Gibco-BRL); 2.5 nM
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calyculin A (Gibco-BRL); 10 nM sodium vanadate; 50 nM phorbol
(12,13-dibutyroyl) (PMA, Serva); 200 nM lovastatin; 10 WM forskolin
(Sigma); 4 ng/ml transforming growth factor L1 (TGF L1). Serum
treatment was performed by incubating the cells in 20% (v/v) foetal
calf serum for 24 h after 17 h of serum starvation.
2.4. Immuno£uorescence
Cells were ¢xed in 4% (v/v) formaldehyde in PBS for 20 min. In-
direct immuno£uorescence was performed using as ¢rst antibodies
either FN-3E2 (Sigma), a mouse monoclonal against EDI epitopes,
or a rabbit polyclonal against human FN (Gibco-BRL) that also
recognises other vertebrate FNs.
2.5. Northern blot
Total RNA was extracted from cell monolayers using the acid gua-
nidinium thiocyanate-phenol-chloroform procedure [18]. RNAs were
electrophoresed in 1% agarose and 2.2 M formaldehyde gels, vacuum
transferred to a nylon membrane (Hybond N) and hybridised at 68‡C
in 50% (v/v) formamide, 7% (w/v) SDS, 120 mM phosphate bu¡er
(pH 7), 250 mM NaCl, 10% (v/v) PEG with an FN riboprobe [19].
2.6. RT-PCR ampli¢cation
One Wg of total RNA was used as template for M-MLV reverse
transcriptase (300 U) in a 20-Wl reaction containing 50 mM Tris-HCl
(pH 8.3), 75 mM KCl, 3 mM Mg2Cl, 10 mM DTT, 20 U of RNasin
(Promega), 400 WM dNTPs, 3 mM pdT12ÿ18 (Pharmacia), at 35‡C for
1 h. PCR ampli¢cation of mouse FN cDNA was performed with
20 WM primers mFAdir (5P-CAGAAATGACCATTGAAGGT-3P)
and mFArev (5P-ATGAGTCCTGACACAATCAC-3P), 1.5 mM
MgCl2, 200 WM dNTPs and 1.5 U of Taq DNA polymerase. PCR
consisted of 30 cycles of 60 s at 94‡C, 60 s at 50‡C and 60 s at 72‡C.
RT-PCR products were electrophoresed in 1.8% agarose native gels
and detected by ethidium bromide staining.
2.7. Single strand conformation analysis (SSCA)
SSCA was performed essentially as described by She⁄eld et al. [20],
using the following primers designed for the mouse FN promoter:
forward, 5P-TTTGTTCGGGGCGAACCCAC-3P ; reverse, 5P-CCTT-
TTCTCCCCCTGTGCAG-3P. These primers amplify a region com-
prised between positions 3183 and +45. PCR was performed with 100
ng of genomic DNA, 1 WM primers, 1.5 mM MgCl2, 0.2 mM dNTPs
(including 2 WCi of 3000 Ci/mmol [K-32P]dATP per 50 Wl reaction) and
1.5 U of Taq DNA polymerase. PCR consisted of 30 cycles of 45 s at
94‡C, 30 s at 60‡C and 45 s at 42‡C. Five microliters of product were
denatured in 95% (v/v) formamide at 95‡C for 3 min, and loaded onto
a 6% polyacrylamide non-denaturing, 0.5U TBE gel. Electrophoresis
was performed at room temperature, at 2 W overnight. Gels were
dried and autoradiographed.
2.8. Transfections and CAT assays
Segments of the human FN promoter (3224 to +64) were linked to
the chloramphenicol acetyltransferase (CAT) gene. These constructs
were used to transfect the M3 and MM3 cells. Cells were co-trans-
fected with either cytomegalovirus (CMV)-L-galactosidase, Rous sar-
coma virus (RSV)-L-galactosidase, or pCH110(SV40)-L-galactosidase
reporter plasmids as measure of transfection e⁄ciency. M3 and MM3
cells were transfected with 8 Wl of lipofectamine (Gibco-BRL) and 2 Wg
of plasmid DNA in 35-mm tissue culture dishes. Cells were harvested
48 h post-transfection. Cell extracts and CAT assays were as previ-
ously described [21].
2.9. Quanti¢cation of autoradiograms
Bands in autoradiograms were scanned with a UMAX Scanner and
quantitated densitometrically using the NHI image software.
3. Results
3.1. Downregulation of FN in MM3 cells
Previous to the investigation of FN transcriptional control,
we applied procedures more sensitive than used before [12] to
study the di¡erences in FN and FN mRNA expression be-
tween M3 and MM3 cells. FN can be clearly detected in the
extracellular matrix of M3 cultures by immuno£uorescence,
using either anti-total FN (Fig. 1A, a) or anti-EDI antibodies
(Fig. 1A, b). The extra domain 1 (EDI, also termed EDA) is a
FN internal segment encoded by an alternatively spliced exon,
characteristic of proliferating cells, but absent from FNs of
most resting adult tissues, including plasma FN [22]. In con-
trast, staining of MM3 primary cultures was completely neg-
ative (Fig. 1A, c and d) with both antibodies. These results
correlated well with the lack of detection of full length FN
mRNA in MM3 cells by Northern blot (Fig. 1B, lane 2) in
comparison to the strong signal observed in M3 cells (Fig. 1B,
lane 1). However, using the more sensitive RT-PCR procedure
we were able to detect low amounts of FN mRNA in MM3
cells, which suggests that the FN gene is indeed transcribed in
these cells. The use of RT-PCRs of increasing number of
cycles and ribosomal RNA as internal control allowed us to
estimate that the levels of FN mRNA are at least 40-fold
lower in MM3 cells than in M3 cells (Fig. 1C). Noticeably,
EDI/EDI3 FN mRNA ratio is 4-fold higher in the moder-
ately metastatic M3 cells than in the highly metastatic MM3
cells, which suggests a change in alternative mRNA splicing.
3.2. Activation of various signal cascades has no e¡ect on FN
mRNA levels in MM3 cells
Assuming that the same regulatory factors were a¡ecting
negatively the endogenous and transfected FN promoters we
performed a series of experiments aiming to activate the en-
dogenous gene by a¡ecting di¡erent signal transduction cas-
cades. FN mRNA levels of MM3 cells, measured by Northern
blot or RT-PCR, were not a¡ected by treatment of cell mono-
layers with protein Ser/Thr phosphatase inhibitors such as
okadaic acid or calyculin A; an inhibitor of protein Tyr phos-
phatases (vanadate); activators of protein kinase (PK) path-
ways such as PMA (PKC) and forskolin (PKA); an inhibitor
of small GTP-binding protein isoprenylation (lovastatin); se-
rum starvation followed by incubation with 20% (v/v) foetal
calf serum; and a growth factor known to activate the FN
gene in other cell types (TGF L1) [23] (results not shown, see
Section 2 for treatment conditions).
3.3. Promoter sequence analysis
The proximal 220 bp of the FN gene promoters of human
and rodents are highly conserved and contain most of the key
cis regulatory elements: a cyclic AMP response element
(CRE) at position 3170, a CCAAT box at position 3150,
two AP-2 sites at positions 357 and 3124, two Sp1 sites at
positions 399 and 394 and a canonical TATA box at 325
(numbering corresponds to the human gene). Cooperativity
between the neighbouring CRE and CCAAT sites has been
extensively studied in our laboratory [24,25]. Introduction of
disruptive point mutations into the CRE and CCAAT sites in
the context of the proximal 220 bp reduces transcriptional
activity by at least 80% in FN promoter-chloramphenicol ace-
tyl transferase (FN-CAT) constructs transfected in various
cell lines of either mesenchymal (NIH 3T3, HT1080) or epi-
thelial (Hep3B, HepG2) origins (C.G. Pesce and A.R.K.,
manuscript submitted). So, this region ¢ts the de¢nition of
promoter proposed by Blackwood and Kadonaga [26] and is
a good candidate to investigate a putative negative transcrip-
tional regulation in MM3 cells. To determine if the extremely
low levels of FN mRNA in MM3 cells were due to disruptive
mutations in the 220-bp proximal region of the endogenous
FN gene we performed single strand conformation analysis
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(SSCA) of this region using genomic DNAs from normal
mouse liver, M3 and MM3 cell cultures. Fig. 2A shows that
the same band pattern is observed with templates from the
three cell types. We then subcloned the same PCR products
used for SSCA into a CAT expression vector (pUC19-CAT-0)
and sequenced the inserts of 5 independent subclones for each
cell type. All inserts showed the same sequence, which is iden-
tical to the published mouse sequence [27]. This indicates that
downregulation of FN mRNA in MM3 cells cannot be attrib-
uted to structural defects of the FN promoter proximal re-
gion. A signi¢cant deletion or insertion outside this region has
been ruled out previously [12].
3.4. Transient expression of FN-CAT constructs
The high degree of conservation between human and mouse
promoter sequences allowed us to use indistinctly mouse FN-
CAT or previously characterised human FN-CAT constructs
[21,25] to investigate whether downregulation occurred at the
transcriptional level. Since we found that MM3 cells have
lower transfection e⁄ciencies than M3 cells, we took special
care in estimating them by co-transfecting FN-CAT con-
structs in separate experiments with plasmids in which the
L-galactosidase (L-gal) reporter is under the control of di¡er-
ent viral promoters. Fig. 3A shows that transcriptional activ-
ity of p-220-CAT is much higher in M3 cells (lanes 3, 5 and 7)
than in MM3 cells (lanes 4, 6 and 8), independently of the
promoter nature of the L-gal construct used for standardising
transfection (Early Simian Virus 40 (SV40), lanes 3 and 4;
Rous Sarcoma Virus Long Terminal Repeat (RSV), lanes 5
and 6; Immediate Early Cytomegalovirus (CMV), lanes 7 and
8)). Consistently, similar CAT activities were observed when
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Fig. 2. Fibronectin promoter analysis in M3 and MM3 cells. A:
Single-strand conformation analysis of PCR products obtained by
ampli¢cation of the FN proximal promoter region of genomic DNA
from mouse liver, M3 or MM3 cells. Left lanes of each pair corre-
spond to controls in which DNA was not denatured prior to load-
ing the non-denaturing polyacrylamide gel, and show the expected
RT-PCR product of 228 bp.
Fig. 1. A: Indirect immuno£uorescence of M3 (a and b) and MM3 (c and d) cell monolayers with antibodies directed to total plasma FN (a
and c) or the alternatively spliced EDI segment (b and d), characteristic of pericellular FN. B: Northern blot of total RNA from M3 (lane 1)
and MM3 (lane 2) cells, hybridised with an FN riboprobe. The bottom panel shows ethidium bromide staining. C: RT-PCR of di¡erent num-
bers of cycles of total RNA from M3 (lanes 1^3, 7 and 8) or MM3 (lanes 4^6, 9 and 10) cells, using primers designed to detect EDI and
EDI3 splicing isoforms of mouse FN mRNA (lanes 1^6) or control 28S ribosomal RNA (lanes 7^10). Bars indicate EDI/EDI3 ratios result-
ing from quanti¢cation of bands in lanes 3 and 6.
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M3 or MM3 cells were transfected with a CMV-CAT con-
struct (Fig. 3A, lanes 11 and 12), indicating that, unlike the
FN promoter, the CMV promoter is equally active in both
cell types. Similar results were obtained using the mouse FN
promoter-CAT construct instead of human p-220-CAT (Fig.
3C). These results suggest that the very low transcriptional
activity observed in MM3 cells involves cis elements located
within the 220-bp proximal promoter region. Inclusion of up-
stream promoter sequences of up to 3500 (Fig. 3B, lanes
5 and 6) or 31600 (lanes 7 and 8) in the CAT constructs
increased transcriptional activity in M3 cells but did not over-
ride the low expression observed in MM3 cells.
4. Discussion
Several lines of evidence indicate that reduction of FN pro-
duction in metastasising cells in comparison to their non-
metastasising variants is not merely a circumstantial event.
This idea is supported not only by the inverse correlation
between FN production and metastatic potential observed in
several tumour cell types [12,28] but most importantly by a set
of independent experiments designed to perturb FN-integrin
interactions both in vivo and in vitro. Injection of RGD-con-
taining peptides [3] or anti-FN antibodies [4] into mice, treat-
ment of metastatic cells with super-FN previously to injection
into mice [11], intraperitoneal injection of super-FN into mice
previously to challenge with metastatic cells [11] and trans-
genic overexpression of FN in highly metastatic cells [6] in-
hibit metastasis. On the contrary inhibition of FN synthesis
by antisense RNA abrogates the suppression of malignancy
induced by the hybridisation of melanoma cells with normal
¢broblasts [29]. Similarly, FN mRNA levels were 8-fold lower
in cells induced to metastasise by transfection with the v-Ha-
ras oncogenes [28].
Several mechanisms could account for reduction in FN
steady state levels in more metastatic cells. Impaired FN syn-
thesis could be the result of selection of subpopulations of
tumour cells in which the FN gene or any of its positive
regulator genes have su¡ered disruptive mutations. Negative
regulation of transcription, splicing or translation induced by
viruses, oncogenes or external signals could a¡ect directly the
FN information £ow or that of a positive regulatory factor.
Alternatively, an increase in enzymes that degrade FN or alter
FN mRNA stability would cause similar e¡ects. It is quite
plausible that two or more of these processes act in a con-
certed way in a particular cell type.
In this context, unravelling the inhibitory mechanisms be-
comes crucial for the development of therapeutic strategies to
inhibit metastasis. The work of Pasqualini et al. [11] leads the
way to a potential use of super-FN as a powerful antimeta-
static agent with apparently no toxic e¡ects on normal cells.
Other strategies may include the development of drugs that
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Fig. 3. Downregulation of FN in MM3 cells. Transient expression of FN-CAT constructs in M3 (odd numbered lanes) and MM3 (even num-
bered lanes) cells. A: Cells were transfected with p-220 CAT (lanes 3^8) by the lipofectamine method, cotransfecting with three di¡erent L-gal-
actosidase expressing constructs as e⁄ciency controls: SV40-Lgal (lanes 3 and 4), RSV-Lgal (lanes 5 and 6) and CMV-Lgal (lanes 7 and 8).
Control transfections with a CMV-CAT construct are shown in lanes 11 and 12. B: Cells were transfected with three FN-CAT constructs dif-
fering in the length of the promoter region: p-220 CAT (lanes 3 and 4), p-500 CAT (lanes 5 and 6) and p-1600 CAT (lanes 7 and 8). C: Cells
were transfected with a 220-bp mouse FN promoter-CAT construct (lanes 3 and 4). In all panels lanes 1 and 2 are mock transfections with no
DNA added. For experimental details see Section 2.
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stimulate endogenous FN expression or prevent downregula-
tion.
We show here that the loss of FN expression in MM3 cells
is not caused by changes in the FN promoter sequence, but is
the result of negative transcriptional regulation. We failed to
revert this downregulation by treating MM3 cells with di¡er-
ent agents that activate signal transduction cascades, includ-
ing protein phosphatase inhibitors, protein kinase activators,
small GTP-binding protein inhibitor, serum and TGF L1.
The observed decrease in transcription activity observed in
FN-CAT transfections accounts for the 40-fold reduction in
steady state levels of FN mRNA, leaving little room for post-
transcriptional mechanisms as those caused by Ha-Ras in hu-
man osteosarcoma cells [31].
Adenovirus protein E1a, cyclic AMP and v-Src were re-
ported to repress FN gene transcription. However, very little
is known about these negative regulations. Expression of E1a
causes oncogenic transformation and brings down FN tran-
scription in 3Y1 rat ¢broblasts [30]. Since both E1a splicing
variants (13S and 12S) are equally able to repress the FN
promoter, this e¡ect is not related to the more characterised
transcriptional activating role of E1a, which requires the do-
main that is absent in the 12S variant (named CR3), that acts
through ATF/CRE sites. Oda and co-workers showed that
E1a transformed 3Y1 cells possess a protein, termed G10-
BP, that binds to G-rich sequences of the FN promoter, co-
incident with SP-1 sites. G10-BP might act as a transcriptional
repressor by displacement of the ubiquitous activator SP-1
from its cognate site [32].
In the case of v-Src, a distal portion of the rat FN gene
promoter (3.9 kb) has been implicated in mediating a 3^4-fold
inhibition of FN transcription initiation caused by expression
of p60vÿsrc in NRK cells [33].
Fig. 3 shows that the proximal 220-bp region of either the
human or mouse FN promoters are su⁄cient to mediate tran-
scriptional downregulation in MM3 cells. Inclusion of addi-
tional upstream sequences does not override low transcrip-
tional activity. Our results cannot rule out species-speci¢c
regulation for regions upstream of 3220. Apart from the al-
ready mentioned SP-1 site, the 200-bp proximal promoter
region contains the major CRE and an adjacent CCAAT
motif. Cooperative interaction between the CRE and CCAAT
sites has been reported in liver cells [24], involving the tran-
scription factors ATF-2, NF-1 and CP-1 [25]. This interaction
is also observed in cell types of non-hepatic origin, but it
seems to be functionally important in liver cells since it medi-
ates transcriptional activation by cAMP in the hepatoma cell
line Hep3B, but not in ¢broblasts (C.G. Pesce and A.R.K.,
manuscript submitted). We were not able to detect di¡erences
between M3 and MM3 nuclear extract binding to the SP1,
CRE and CCAAT sites of the FN promoter, assessed by gel
mobility shift or DNase I footprinting (data not shown). This
indicates that the decrease in the FN promoter activity in
MM3 cells must be the result of more subtle changes in the
quality of trans-acting factors.
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